Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
Mycobacterium tuberculosis (Mtb) is known to cause TB. CAT-5571 will be studied alone and in combination with the standard of care regimen in cell and animal models of Mtb infection to determine the potential for CAT-5571 to induce autophagy and encourage Mtb elimination as well as to assess its contribution to TB drug regimens and durations.
In previous preclinical studies, CAT-5571 was shown to restore autophagy in mouse and human cells with the delta508-CFTR mutation and promote the clearance of bacteria, including Mycobacterium abscessus, from these cells. Evidence suggests that autophagy plays a crucial role in antimycobacterial resistance in TB by acting as an alternative mechanism to control Mtb infection in macrophages, as well as to defend and counteract Mtb evasion strategies.
“We are thrilled to work with Gates MRI to expand our understanding of CAT-5571,” said
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the anticipated results from the research program and CTA-5571 as a potential treatment for TB and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may” and similar expressions, constitute forward-looking statements under applicable securities laws and regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties related to the impact of the COVID-19 pandemic, uncertainties inherent in the initiation and completion of research programs and studying a potential therapy for a potential new indication, and other factors discussed in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the period ended
Catabasis Investor and Media Contact
T: (617) 349-1971